Unleashing meaningful innovation through regulatory reform

The first in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.

What effect do the shortcomings of current assessment processes have on the quality of innovation?

How do we resolve the conundrum of high prices and high uncertainty?

Our panelists discussed how regulatory and payment systems could be adapted to incentivise the timely generation of quality comparative data on the benefits and harms of new drugs and high-risk devices both before and after their market entry, profiting patients, clinicians, and healthcare systems.